ANI CFO exercises options, sells 3,313 shares
ANI Pharmaceuticals SVP & CFO Stephen P. Carey exercised options and sold shares in a planned transaction.
Rhea-AI Filing Summary
ANI Pharmaceuticals SVP & CFO Stephen P. Carey exercised options and sold shares in a planned transaction. On July 2, 2026, he exercised a stock option for 3,313 shares of common stock at $49.51 per share and sold 3,313 shares in an open-market transaction at $86 per share. The exercise and sale were made under a Rule 10b5-1 trading plan adopted on March 6, 2026. Following these transactions, he directly holds 177,543 shares of ANI Pharmaceuticals common stock. The option had vested in four 25% installments on March 31 of 2018, 2019, 2020, and 2021 and carries an expiration date of March 30, 2027.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 3,313 shares ($121K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
CAREY STEPHEN P.
Role
SVP & CFO
Sold
3,313 shs ($285K)
Approx. gross sale proceeds
$285K
Approx. exercise cost
$164K
Approx. pre-tax spread
$121K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) | 3,313 | $49.51 | $164K |
| Exercise | Common Stock | 3,313 | $49.51 | $164K |
| Sale | Common Stock | 3,313 | $86.00 | $285K |
Holdings After Transaction:
Stock Option (right to buy) — 3,313 contracts (Direct);
Common Stock — 177,543 shares (Direct)
Footnotes (2)
- F1. The stock option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2026.
- F2. 25% of the total options vested on each of March 31, 2018, March 31, 2019, March 31, 2020, and March 31, 2021.
Key Figures
Shares sold: 3,313 shares
Sale price: $86.00 per share
Shares exercised: 3,313 shares
+3 more
6 metrics
Shares sold
3,313 shares
Open-market sale of common stock on July 2, 2026
Sale price
$86.00 per share
Price for 3,313 common shares sold
Shares exercised
3,313 shares
Common stock acquired via option exercise
Exercise price
$49.51 per share
Stock option (right to buy) exercise price
Post-transaction holdings
177,543 shares
Common stock directly owned after transactions
Option expiration
March 30, 2027
Expiration date of exercised stock option
Key Terms
Rule 10b5-1 trading plan, Stock Option (right to buy), open-market sale, derivative security, +1 more
5 terms
Rule 10b5-1 trading plan financial
"The stock option exercise and sale ... were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2026."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Stock Option (right to buy) financial
"security_title": "Stock Option (right to buy)""
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
derivative security financial
"transaction_code_description": "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
expiration_date financial
"expiration_date": "2027-03-30T00:00:00.000Z""
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did ANI Pharmaceuticals (ANIP) report for its CFO?
ANI Pharmaceuticals reported that SVP & CFO Stephen P. Carey exercised options and sold shares. He exercised 3,313 stock options and sold 3,313 common shares in an open-market transaction on July 2, 2026, under a Rule 10b5-1 plan.
What stock options did the ANI Pharmaceuticals (ANIP) CFO exercise in this Form 4?
Stephen P. Carey exercised a stock option covering 3,313 shares of ANI Pharmaceuticals common stock at an exercise price of $49.51 per share. The option expires on March 30, 2027, and had vested in four 25% tranches from 2018 through 2021.
Was the ANI Pharmaceuticals (ANIP) CFO’s sale under a Rule 10b5-1 trading plan?
Yes. The Form 4 footnotes state the stock option exercise and sale were effected under a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2026, indicating the trades were pre-planned rather than opportunistic.
What was the vesting schedule for the ANI Pharmaceuticals (ANIP) options exercised?
The exercised options vested in four equal installments of 25% each on March 31, 2018, March 31, 2019, March 31, 2020, and March 31, 2021. This schedule reflects gradual vesting over four years before the July 2026 exercise.
AI-generated analysis. How Rhea-AI works. Not financial advice.
